Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» psoriasis
psoriasis
J&J looks for the inside story with new online psoriasis campaign
J&J looks for the inside story with new online psoriasis campaign
Fierce Pharma
JNJ
psoriasis
Janssen
drug marketing
Flag link:
Novartis star Cosentyx, facing new rivals, may gain edge as a disease-modifying med
Novartis star Cosentyx, facing new rivals, may gain edge as a disease-modifying med
Fierce Pharma
Novartis
Cosentyx
psoriasis
Eli Lilly
Taltz
Valeant Pharmaceuticals
Siliq
Flag link:
Does Valeant have the ad dollars to keep Siliq competitive in psoriasis?
Does Valeant have the ad dollars to keep Siliq competitive in psoriasis?
Fierce Pharma
Valeant Pharmaceuticals
Siliq
psoriasis
direct ads
DTC ads
Flag link:
J&J may be late to the psoriasis drug market party, but it’s planning to make a splash with guselkumab
J&J may be late to the psoriasis drug market party, but it’s planning to make a splash with guselkumab
Endpoints
JNJ
psoriasis
guselkumab
Flag link:
Purdue Pharma Puts Skin In The Game With Psoriasis Deal
Purdue Pharma Puts Skin In The Game With Psoriasis Deal
Seeking Alpha
Purdue Pharma
psoriasis
AST-005
antisense
Exicure
Flag link:
Are DTC ads tipping the balance in psoriasis battle between Lilly’s Taltz and Novartis’ Cosentyx?
Are DTC ads tipping the balance in psoriasis battle between Lilly’s Taltz and Novartis’ Cosentyx?
Fierce Pharma
DTC advertising
psoriasis
Eli Lilly
Novartis
Taltz
Cosentyx
Flag link:
FDA OKs Expanded Use of Amgen's Enbrel
FDA OKs Expanded Use of Amgen's Enbrel
Investopedia
FDA
Amgen
Enbrel
pediatrics
psoriasis
Flag link:
Eli Lilly’s new psoriasis treatment Taltz launches first ads, chasing Novartis’ Cosentyx lead
Eli Lilly’s new psoriasis treatment Taltz launches first ads, chasing Novartis’ Cosentyx lead
Fierce Pharma
Eli Lilly
psoriasis
Novartis
Cosentyx
Taltz
drug ads
Flag link:
This Looks to Be Johnson & Johnson's Next Blockbuster Drug
This Looks to Be Johnson & Johnson's Next Blockbuster Drug
Motley Fool
JNJ
psoriasis
guselkumab
Flag link:
J&J psoriasis drug tops placebo, Humira in late stage study
J&J psoriasis drug tops placebo, Humira in late stage study
Yahoo/Reuters
JNJ
psoriasis
Humira
AbbVie
guselkumab
Flag link:
Celgene's Otezla Is A Big Hit
Celgene's Otezla Is A Big Hit
Motley Fool
Celgene
Otezla
psoriasis
Flag link:
Valeant gets FDA panel recommendation for psoriasis drug
Valeant gets FDA panel recommendation for psoriasis drug
Marketwatch
Valeant Pharmaceutcals
FDA
advisory panels
psoriasis
brodalumab
Flag link:
FDA review details suicides, cardio risks linked to Valeant’s $100M drug brodalumab
FDA review details suicides, cardio risks linked to Valeant’s $100M drug brodalumab
Endpoints
FDA
Valeant Pharmaceuticals
suicide
brodalumab
psoriasis
Flag link:
Valeant - Baby Steps Back To Prosperity
Valeant - Baby Steps Back To Prosperity
Seeking Alpha
Valeant Pharmaceuticals
brodalumab
psoriasis
Flag link:
AstraZeneca Transfers Valeant's European Rights To Troubled Drug
AstraZeneca Transfers Valeant's European Rights To Troubled Drug
Investors.com
AstraZeneca
Valeant Pharmaceuticals
brodalumab
psoriasis
Flag link:
2 Biotech Companies That Could Profit if Their Skin Treatments Are Successful
2 Biotech Companies That Could Profit if Their Skin Treatments Are Successful
TheStreet.com
Regeneron
dupilumab
Anacor
Crisaborole Topical Ointment
psoriasis
eczema
Flag link:
FDA approves Eli Lilly drug for psoriasis
FDA approves Eli Lilly drug for psoriasis
Yahoo/Reuters
FDA
Eli Lilly
psoriasis
ixekizumab
Flag link:
J&J psoriasis drug Stelara tames Crohn's disease in second trial
J&J psoriasis drug Stelara tames Crohn's disease in second trial
Yahoo/Reuters
JNJ
psoriasis
Stelara
Crohn's Disease
Flag link:
Novartis' Cosentyx proves superior to Janssen's Stelara in head-to-head comparison
Novartis' Cosentyx proves superior to Janssen's Stelara in head-to-head comparison
BioPharma Dive
Novartis
Cosentyx
Janssen
Stelara
psoriasis
Flag link:
AbbVie to Pay $595 Million for Boehringer Immunology Treatments
AbbVie to Pay $595 Million for Boehringer Immunology Treatments
Bloomberg
AbbVie
Boehringer Ingelheim
M&A
psoriasis
Crohn’s disease
asthma
Flag link:
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
next ›
last »